INDOUSBSEIndo Us Bio-Tech LtdMinimalNeutral
Announced Sat, 30 May · 14:35 IST

Newspaper Publication of Audited Financial Results for the Quarter/ Year ended on 31st March, 2026. Thanks

INDOUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.9%1-day move
₹99.50
prior close
₹98.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.8+1.3+2.0+2.6-0.9-4.7-1.9-2.5-4.2-9.6-6.8-10.8
Up moveDown movePending
AI summary

Indo Us Bio-Tech Ltd has published its audited standalone financial results for Q4 and full year FY2026 ended March 31, 2026. Total income from operations grew by 6.2% to Rs 11,049.33 Lakhs compared to Rs 10,402.04 Lakhs in FY2025. However, profit before tax declined by 15.8% to Rs 1,392.02 Lakhs from Rs 1,653.06 Lakhs. Net profit fell by 19.3% to Rs 1,312.29 Lakhs from Rs 1,626.74 Lakhs. Tax expenses more than tripled to Rs 79.73 Lakhs from Rs 26.32 Lakhs. EPS dropped to Rs 6.54 from Rs 8.11 per share. For Q4 standalone, total income was Rs 3,350.41 Lakhs with net profit of Rs 368.48 Lakhs.

Likely market impact

Revenue growth was offset by significantly higher tax expenses and reduced profitability. Shareholders may see negative sentiment as earnings per share declined nearly 20% year-on-year despite higher sales.